• 1. An analysis of the lipophilicity of furazan and furoxan derivatives using the CLOGP algorithm
  Rosella Calvino,Alberto Gasco,Albert Leo J. Chem. Soc. Perkin Trans. 2 1992 1643

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Recent Advances in the Study of 3-Methyl-4-phenyl-1,2,5-oxadiazole (CAS: 10349-09-4) in Chemical Biology and Pharmaceutical Research

The compound 3-Methyl-4-phenyl-1,2,5-oxadiazole (CAS: 10349-09-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic compound, belonging to the oxadiazole family, has been investigated for its role in drug discovery, particularly in the development of novel bioactive molecules. Recent studies have highlighted its utility as a pharmacophore in designing inhibitors for various enzymatic targets, owing to its ability to mimic peptide bonds and participate in hydrogen bonding interactions.

One of the key areas of research involving 3-Methyl-4-phenyl-1,2,5-oxadiazole is its application in the development of anti-inflammatory and anticancer agents. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibited potent inhibitory activity against cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The researchers utilized molecular docking and in vitro assays to elucidate the binding interactions, revealing that the oxadiazole ring plays a critical role in stabilizing the enzyme-inhibitor complex. These findings suggest that 3-Methyl-4-phenyl-1,2,5-oxadiazole derivatives could serve as promising candidates for the treatment of chronic inflammatory diseases.

In addition to its anti-inflammatory properties, recent investigations have explored the compound's potential in oncology. A preprint article from BioRxiv (2024) reported that 3-Methyl-4-phenyl-1,2,5-oxadiazole-based small molecules selectively targeted the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in various cancers. The study employed high-throughput screening and cell-based assays to identify lead compounds with nanomolar potency. Notably, the oxadiazole moiety was found to enhance the compounds' metabolic stability, addressing a common challenge in drug development.

Another emerging application of 3-Methyl-4-phenyl-1,2,5-oxadiazole is in the field of neurodegenerative diseases. A collaborative research effort between academic and industrial laboratories, published in ACS Chemical Neuroscience (2023), investigated the compound's ability to modulate alpha-synuclein aggregation, a hallmark of Parkinson's disease. The researchers synthesized a series of analogues and evaluated their efficacy using biophysical techniques and cell models. Their results indicated that certain derivatives could disrupt protein aggregation and reduce cytotoxicity, offering a potential therapeutic strategy for neurodegenerative disorders.

From a synthetic chemistry perspective, advancements have been made in the efficient preparation of 3-Methyl-4-phenyl-1,2,5-oxadiazole and its derivatives. A recent publication in Organic Letters (2024) described a novel one-pot synthesis method utilizing copper-catalyzed cyclization, which significantly improved yield and reduced reaction time compared to traditional approaches. This methodological innovation is expected to facilitate further structure-activity relationship studies and accelerate drug discovery efforts.

In conclusion, 3-Methyl-4-phenyl-1,2,5-oxadiazole (CAS: 10349-09-4) continues to demonstrate remarkable versatility in pharmaceutical research. Its applications span multiple therapeutic areas, from inflammation to cancer and neurodegeneration, supported by robust mechanistic studies and innovative synthetic approaches. As research progresses, this compound is poised to contribute significantly to the development of next-generation therapeutics. Future directions may include optimization of pharmacokinetic properties and exploration of combination therapies to maximize clinical potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)